Stay updated on STK-012 in Solid Tumors with Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page.

Latest updates to the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page
- Check5 days agoChange DetectedThe record history now shows a new revision tag (v3.6.2), replacing the previous v3.6.0, indicating the study record has been updated.SummaryDifference0.1%

- Check12 days agoChange DetectedThe newer version deletes several core study-record sections (Contacts/Locations, Study Status, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Conditions, Study Description, Oversight, Study Identification, Recruitment Status) that together define how the trial is conducted and presented.SummaryDifference11%

- Check19 days agoChange DetectedThe page adds quick-access links 'Check who can join' and 'Find Contact Information' and updates the revision label from v3.5.5 to v3.6.0, representing a small UI/branding update in the study history.SummaryDifference0.4%

- Check26 days agoChange DetectedRevision: v3.5.5 replaces v3.5.4 in the record history, marking a new platform release. It does not alter trial data or study details.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page displays Revision: v3.5.4, replacing the previous v3.5.3. This indicates a new ClinicalTrials.gov release rather than changes to the study details.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page's revision history shows a new version, v3.5.3, added to the records. This reflects a small system update rather than substantive changes to study information.SummaryDifference0.1%

Stay in the know with updates to STK-012 in Solid Tumors with Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the STK-012 in Solid Tumors with Pembrolizumab Clinical Trial page.